Revs would be great. However, here's the reality:
Post# of 36537
(Total Views: 332)
Posted On: 02/25/2021 1:11:04 PM
Revs would be great. However, here's the reality:
1) Excellagen is dead in the water
2) NuGen Health was supposed to be generating at least a trickle of revs by Thanksgiving that would continue to grow w the rollout. With no news, I can only assume there is nothing there.
3) Every other GNBT project is sitting on the shelf until we have $ to kick them into gear.
4) Most of the "up-front" vaccine money that remains is not payable until there is an approved vaccine. Same obviously for dose royalty payments.
So the way I see it, these are the three most important things for our SP:
A) IPO,
2) IPO, and
d) IPO.
Regarding the IPO:
- The NGIO valuation has been available for ~6 weeks. Joe said that was the last missing piece.
- Joe has presumably been working behind the scenes on pricing (incorporating vaccine progress) and securing investors
- We were told the S-1s for NGIO were ready and "EFFECT" dates needed to be selected. Where is the re-submittal with the pricing?
- Might need a little time to straighten out div shares for shareholders before first trade date.
- It appears that Naz requirements would be met if the above and other clerical items are taken care of.
This is the linchpin. Let's hear some news and hit that mid-March IPO guesstimate from the interview.
1) Excellagen is dead in the water
2) NuGen Health was supposed to be generating at least a trickle of revs by Thanksgiving that would continue to grow w the rollout. With no news, I can only assume there is nothing there.
3) Every other GNBT project is sitting on the shelf until we have $ to kick them into gear.
4) Most of the "up-front" vaccine money that remains is not payable until there is an approved vaccine. Same obviously for dose royalty payments.
So the way I see it, these are the three most important things for our SP:
A) IPO,
2) IPO, and
d) IPO.
Regarding the IPO:
- The NGIO valuation has been available for ~6 weeks. Joe said that was the last missing piece.
- Joe has presumably been working behind the scenes on pricing (incorporating vaccine progress) and securing investors
- We were told the S-1s for NGIO were ready and "EFFECT" dates needed to be selected. Where is the re-submittal with the pricing?
- Might need a little time to straighten out div shares for shareholders before first trade date.
- It appears that Naz requirements would be met if the above and other clerical items are taken care of.
This is the linchpin. Let's hear some news and hit that mid-March IPO guesstimate from the interview.
(7)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼